LISTING OF CLAIMS

1. (Previously Presented) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of a substantially pure form of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent,

wherein said hydroxylated atorvastatin metabolite is selected from the group consisting of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(4-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(3-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(2-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and wherein the effective amounts of amlodipine and hydroxylated atorvastatin metabolite synergistically inhibit lipid peroxidation in human low density lipoprotein or lipid membrane to achieve a therapeutic effect.

2. (Cancelled)

3. (Previously Presented) The pharmaceutical composition of claim 1 wherein said amlodipine comprises amlodipine besylate.

4. (Previously Presented) The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to

synergistically inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of reducing the risk of arterial and related heart disease.

5. (Original) The pharmaceutical composition of claim 4 wherein said arterial and related heart disease is selected from the group consisting of hypertension, hyperlipidemia, atherosclerosis, arteriosclerosis, coronary artery disease, myocardial infarction, congestive heart failure, stroke, and angina pectoris.

6. (Previously Presented) The pharmaceutical composition of claim 1 wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to synergistically inhibit lipid peroxidation.

7.- 28. (Cancelled)

29.-56. (Cancelled)

57.-59. (Cancelled)

60.-62. (Cancelled)

63. (Previously Presented) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of a substantially pure form of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said hydroxylated atorvastatin metabolite is selected from the group consisting of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(4-hydroxyphenyl)-4-phenyl-1-[2-

(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(3-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(2-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that a synergistic antioxidant effect is achieved.

64. (Previously Presented) A pharmaceutical composition comprising:

an effective amount of amlodipine;

an effective amount of a substantially pure form of hydroxylated atorvastatin metabolite; and

a pharmaceutically acceptable carrier or diluent;

wherein said hydroxylated atorvastatin metabolite is selected from the group consisting of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(4-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(3-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N-(2-hydroxyphenyl)-4-phenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, and wherein said effective amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that a synergistic inhibition of lipid peroxidation is achieved.

65. (Previously Presented) The pharmaceutical composition of claim 64 wherein said selection is further coordinated for achieving a synergistic antioxidant effect.

66. (Previously Presented) The pharmaceutical composition of claim 63, wherein said composition is used to treat atherosclerosis.

67. (Previously Presented) The pharmaceutical composition of claim 66, wherein said atherosclerosis involves diseases selected from the group consisting of myocardial

infarction, stroke, transient ischemic attack, coronary heart disease and a combination thereof.

68. (Previously Presented) The pharmaceutical composition of claim 63 further comprising an effective amount of a lipophilic antioxidant.